STOCK TITAN

BioRestorative expects Q3 delay beyond 5-day extension

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. (BRTX) said it cannot file its Form 10-Q for the quarter ended September 30, 2026, on time and does not expect to file within the five-day extension. The company says the delay follows its new accounting firm’s audits of the 2024 and 2025 financial statements, which must be completed before it can finish reviews of the June and September 2026 interim statements. The June 2026 Form 10-Q also remains unfiled.

The company anticipates third-quarter results may differ materially from the corresponding 2025 period. It cited the August 7, 2026 suspension of orders and shipments for its biocosmeceutical product lines, as well as professional and advisory expenses. It is evaluating potential reporting effects involving former-officer contractual claims and equity awards, inventory and intangible asset recoverability, and revolving-credit borrowings; it has not determined whether these matters will lead to third-quarter charges and cannot yet provide a reasonable quantitative estimate.

Extension period 5 days The company does not expect to file its September 2026 quarterly report within this extension.
Product orders and shipments suspended August 7, 2026 Suspension covered the company’s biocosmeceutical product lines pending a business and regulatory review.
Fiscal years under audit 2024 and 2025 The audits must be completed before reviews of the June and September 2026 interim financial statements.
Rule 12b-25(b) regulatory
"five-day extension period provided by Rule 12b-25(b)"
interim financial statements financial
"reviews of the Company’s interim financial statements"
Interim financial statements are condensed financial reports covering a short period within a fiscal year—commonly a quarter or month—showing a company’s revenue, expenses, cash flow and snapshot of assets and liabilities for that period. They matter to investors because they provide an up-to-date, mid-year scorecard of performance and trends between annual reports, helping spot improving or deteriorating prospects so decisions can be timed appropriately.
revolving credit facility financial
"borrowings under its revolving credit facility"
A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.
intangible assets financial
"recoverability of certain inventory and intangible assets"
Non-physical resources a company owns that help it earn money, such as brand names, patents, customer lists, proprietary software, or trade secrets — think of them as a company’s reputation, recipes, or secret formulas that aren’t bricks and mortar. Investors care because these assets can create long-term income, protect market share, and boost the value of a business even if they don’t appear as cash; strong intangible assets can mean higher future profits and lower risk of competitors copying a company’s advantages.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is BRTX's third-quarter 2026 10-Q late?

The reviews of the June and September 2026 interim financial statements await completion of audits of the 2024 and 2025 financial statements. The company engaged Bush & Associates CPA LLC on August 28, 2026, replacing CBIZ CPAs P.C. The June 2026 quarterly report also remains unfiled.

What could affect BRTX's third-quarter 2026 results?

The company says results may differ materially from the corresponding 2025 period. It cited the August 7, 2026 suspension of orders and shipments for its biocosmeceutical product lines, professional and advisory expenses, and potential reporting effects involving contractual claims, equity awards, asset recoverability and revolving-credit borrowings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

NOTIFICATION OF LATE FILING

 

SEC File Number: 001-37603 CUSIP Number: 090655705

 

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

For Period Ended: September 30, 2026

 

☐ Transition Report on Form 10-K

 

☐ Transition Report on Form 20-F

 

☐ Transition Report on Form 11-K

 

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: Not applicable

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not applicable

 

 

 

 

PART I — REGISTRANT INFORMATION

 

Full Name of Registrant: BioRestorative Therapies, Inc.

 

Former Name if Applicable: Not applicable

 

Address of Principal Executive Office (Street and Number): 40 Marcus Drive, Suite 1

 

City, State and Zip Code: Melville, New York 11747

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

☐(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

☐(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

☐(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

2 

 

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

BioRestorative Therapies, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Q3 Form 10-Q”) within the prescribed time period without unreasonable effort or expense, and does not expect to file the Q3 Form 10-Q within the five-day extension period provided by Rule 12b-25(b).

 

As previously disclosed, on August 28, 2026 the Company engaged Bush & Associates CPA LLC (“Bush CPA”) as its independent registered public accounting firm, replacing CBIZ CPAs P.C. Bush CPA’s engagement includes new audits of the Company’s financial statements for the fiscal years ended December 31, 2024 and 2025, and Bush CPA has advised the Company that its reviews of the Company’s interim financial statements for the quarters ended June 30, 2026 and September 30, 2026 cannot be completed until those audits are complete. As a result, the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Q2 Form 10-Q”) and is unable to complete the Q3 Form 10-Q within the prescribed time period or the five-day extension period.

 

PART IV — OTHER INFORMATION

 

(1)Name and telephone number of person to contact in regard to this notification

 

Anna Skowron   (631)   760-8100
(Name)   (Area Code)   (Telephone Number)

 

(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☐ Yes ☒ No

 

The Company has not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as described in Part III.

 

(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

The Company anticipates that its results of operations for the three and nine months ended September 30, 2026 may differ materially from the corresponding periods of 2025. On August 7, 2026, the Company suspended orders and shipments of its biocosmeceutical product lines pending a business and regulatory review, affecting product sales activity during the quarter. The Company also expects its results to reflect professional and advisory expenses associated with management changes, the engagement of its new independent registered public accounting firm, and the Audit Committee investigation. The Company is evaluating the potential financial reporting effects of former-officer contractual claims and related equity awards, the recoverability of certain inventory and intangible assets, and borrowings under its revolving credit facility. The Company has not yet determined whether, or to what extent, these matters will result in third-quarter charges. Because the reviews of the Company's June 30 and September 30, 2026 interim financial statements and the audits of the fiscal years ended December 31, 2024 and 2025 remain incomplete, the Company is unable to provide a reasonable quantitative estimate of the anticipated changes at this time.

 

3 

 

 

Forward-Looking Statements

 

This Form 12b-25 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the completion of Bush CPA’s audits and reviews, the filing of the Q2 Form 10-Q and the Q3 Form 10-Q, and the Company’s anticipated results of operations. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that Bush CPA’s audits and reviews take longer than currently anticipated, that the Company identifies additional matters requiring evaluation in the course of its financial reporting process, and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

 

BioRestorative Therapies, Inc.

 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026 By: /s/ Mika Grasso
  Name: Mika Grasso
  Title: Interim Chief Executive Officer

 

4 

 

Keep reading